Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Royal Medical Center

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Royal Medical Center head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 403 · Grade C

Royal Medical Center

Visit Royal Medical Center Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 55 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make Royal Medical Center a bad call — it's best for readers who want credentialed md founder with itemized dose-strength pricing. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
57
Transparency
90
72
Access Breadth
93
40
Clinical Oversight
92
62
Track Record
88
47
CoreAge RxBrief Score 94 · 55Royal Medical Center

Price, coverage & the tracker

CoreAge RxRoyal Medical Center
Brief Score94/100 (A)55/100 (C)
Semaglutide$149/moNot disclosed
Tirzepatide$349/moFrom $450/mo (2.5 mg dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

Royal Medical Center: New to the tracker on 1 August 2026. The published line reads From $450/mo (2.5 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.